

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

NALTREXONE-BUPROPION PROLONGED RELEASE TABLETS (Mysimba®) **BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR SECONDARY CARE**

Mid and South Essex CCGs do not support the prescribing of naltrexone-bupropion 8mg/90mg prolonged release tablets (Mysimba®) for managing overweight and obesity in accordance with NICE TA494.

Naltrexone-bupropion (Mysimba®) is licensed as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with an initial Body Mass Index (BMI) of;

- $\geq 30 \text{ kg/m}^2$ (obese), or
- $\geq 27 \text{ kg/m}^2$ to $< 30 \text{ kg/m}^2$ (overweight) in the presence of one or more weight-related co-morbidities (e.g. type 2 diabetes, dyslipidaemia, or controlled hypertension).

Naltrexone-bupropion 8mg/90mg prolonged release tablets (Mysimba®) is **not** recommended by NICE. NICE TA494 states that; *Naltrexone–bupropion is not recommended within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.*

Recommendations:

- Do not start new patients on naltrexone-bupropion 8mg/90mg prolonged release tablets (Mysimba®).
- Patients currently being prescribed naltrexone-bupropion 8mg/90mg prolonged release tablets (Mysimba®) should be reviewed and treatment stopped.

Rationale:

- Clinical trial evidence shows that naltrexone–bupropion with lifestyle measures is more effective than lifestyle measures alone, but its long-term effectiveness is unknown.
- The estimate of cost effectiveness for naltrexone–bupropion with lifestyle measures, compared with lifestyle measures alone, is highly uncertain because of uncertainties in the modelling assumptions. Large numbers of people could be eligible for treatment which could potentially be long-term, leading to high overall costs for naltrexone–bupropion. Therefore, in these circumstances more certainty is needed that naltrexone–bupropion will provide value for the NHS.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA494 Naltrexone–bupropion for managing overweight and obesity. 12 December 2017. Accessed 7 September 2021 https://www.nice.org.uk/guidance/ta494 Summary of Product Characteristics: Mysimba 8mg/90mg prolonged-release tablets 17 June 2021. Accessed 7 September 2021 https://www.medicines.org.uk/emc/product/2684
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC
Date Approved	October 2021
Review Date	October 2026 or earlier subject to any new updates nationally